𝔖 Bobbio Scriptorium
✦   LIBER   ✦

O-249 Evaluation of the efficacy and tolerability of the oral NK1 antagonist aprepitant for the prevention of chemotherapy induced nausea and vomiting: two randomized, double-blind, placebo controlled trials

✍ Scribed by Gralla, Richard J.; Hesketh, Paul J.; Grunberg, Steven M.; Warr, David G.; Roila, Fausto; Chawla, Sant P.; Carides, Alexandra D.; Beck, Klaus; Lawson, Francesca; Horgan, Kevin J.

Book ID
118571639
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
182 KB
Volume
41
Category
Article
ISSN
0169-5002

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Establishing the dose of the oral NK1 an
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
✍ Sant P. Chawla; Steven M. Grunberg; Richard J. Gralla; Paul J. Hesketh; Cindy Ri πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 152 KB

## Abstract ## BACKGROUND The neurokinin‐1 antagonist aprepitant (EMENDβ„’; Merck Research Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea and vomiting when it is given with a 5‐hydroxytryptamine‐3 receptor antagonist and dexamethasone. The current study sought to